Prostate-specific antigen doubling time and response to cabazitaxel in a hormone-resistant metastatic prostate cancer patient

被引：2
|
作者：
Ghosn, Marwan [1 ]
Dagher, Alain [1 ]
El-Karak, Fadi [1 ]
机构：
[1] St Joseph Univ, Dept Hematol Oncol, Fac Med, 894 Blvd Alfred Naccache,Bldg Sehanoui,5th Floor, Beirut, Lebanon
来源：
JOURNAL OF BIOMEDICAL RESEARCH | 2015年 / 29卷 / 05期
关键词：
prostate-specific antigen; doubling time; prostate cancer; cabazitaxel; docetaxel;
D O I：
10.7555/JBR.28.20130148
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
We report a case of metastatic castration-resistant prostate cancer, who received prior treatment with docetaxel and was then given cabazitaxel as salvage therapy. The patient was monitored by prostate-specific antigen doubling time and prostate-specific antigen absolute value. The prostate-specific antigen doubling time was found to be a good response predictor in the patient.
引用
收藏
页码：420 / 422
页数：3
相关论文
共 50 条
  • [21] Prostate Specific Antigen Half-Time and Prostate Specific Antigen Doubling Time as Predictors of Response to Androgen Deprivation Therapy for Metastatic Prostate Cancer COMMENT
    Cummings, James M.
    JOURNAL OF UROLOGY, 2009, 181 (06): : 2525 - 2525
  • [22] Prostate-specific antigen doubling time: A potential surrogate end point in hormone-refractory prostate cancer - Reply
    Dawson, NA
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (05) : 1646 - 1646
  • [23] Hormone-resistant prostate cancer
    Khoury, S
    PROGRES EN UROLOGIE, 2002, 12 (01): : 7 - 18
  • [24] Current applications for prostate-specific antigen doubling time
    Ramirez, Michelle L.
    Nelson, Eric C.
    White, Ralph W. deVere
    Lara, Primo N., Jr.
    Evans, Christopher P.
    EUROPEAN UROLOGY, 2008, 54 (02) : 291 - 302
  • [25] Prostate-specific antigen response to withdrawal of megestrol acetate in a patient with hormone-refractory prostate cancer
    Wehbe, TW
    Stein, BS
    Akerley, WL
    MAYO CLINIC PROCEEDINGS, 1997, 72 (10) : 932 - 934
  • [26] Predicting patient-specific response to adaptive therapy in metastatic castration-resistant prostate cancer using prostate-specific antigen dynamics
    Brady-Nicholls, Renee
    Zhang, Jingsong
    Zhang, Tian
    Wang, Andrew Z.
    Butler, Robert
    Gatenby, Robert A.
    Enderling, Heiko
    NEOPLASIA, 2021, 23 (09): : 851 - 858
  • [27] PSA Decrease with Fulvestrant Acetate in a Hormone-Resistant Metastatic Prostate Cancer Patient
    Gasent Blesa, Joan M.
    Alberola Candel, Vicente
    ONKOLOGIE, 2010, 33 (1-2): : 57 - 59
  • [28] Long-Term Prostate-Specific Antigen Response on a Low-Dose Cabazitaxel Regimen for Metastatic Castration-Resistant Prostate Cancer: A Case Report
    Kubota, Shigehisa
    Kageyama, Susumu
    Nagasawa, Masayuki
    Wada, Akinori
    Ikari, Ryo
    Tomita, Keiji
    Yoshida, Tetsuya
    Narita, Mitsuhiro
    Kawauchi, Akihiro
    AMERICAN JOURNAL OF CASE REPORTS, 2021, 22
  • [29] Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer
    D'Amico, AV
    Chen, MH
    Cox, MC
    Dahut, W
    Figg, WD
    UROLOGY, 2005, 66 (03) : 571 - 576
  • [30] Dramatic prostate-specific antigen response with activated hemicellulose compound in metastatic castration-resistant prostate cancer
    Turner, Jeffrey
    Chaudhary, Uzair
    ANTI-CANCER DRUGS, 2009, 20 (03) : 215 - 216
12345